Merck KGaA (FRA:MRK) PT Set at €110.00 by JPMorgan Chase & Co.

JPMorgan Chase & Co. set a €110.00 ($123.60) price target on Merck KGaA (FRA:MRK) in a research report report published on Wednesday, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.

A number of other equities analysts have also recently commented on MRK. Goldman Sachs Group set a €94.00 ($105.62) price target on Merck KGaA and gave the stock a sell rating in a research note on Tuesday, July 28th. DZ Bank reissued a buy rating on shares of Merck KGaA in a research note on Wednesday, July 22nd. Nord/LB set a €110.00 ($123.60) target price on Merck KGaA and gave the company a neutral rating in a research note on Friday, May 15th. Barclays set a €90.00 ($101.12) target price on Merck KGaA and gave the company a sell rating in a research note on Wednesday, June 3rd. Finally, Credit Suisse Group set a €125.00 ($140.45) target price on Merck KGaA and gave the company a buy rating in a research note on Wednesday, July 22nd. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. Merck KGaA currently has an average rating of Hold and an average price target of €108.64 ($122.07).

Shares of Merck KGaA stock opened at €108.05 ($121.40) on Wednesday. The business’s 50 day simple moving average is €107.71 and its two-hundred day simple moving average is €106.94. Merck KGaA has a one year low of €76.60 ($86.07) and a one year high of €115.00 ($129.21).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Recommended Story: Terms to Better Understand Call Options

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.